Eptifibatide contraindications: Difference between revisions

Revision as of 22:15, 5 February 2014

Eptifibatide
INTEGRILIN^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Eptifibatide
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Treatment with eptifibatide is contraindicated in patients with:

A history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days.
Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy.
Major surgery within the preceding 6 weeks.
History of stroke within 30 days or any history of hemorrhagic stroke.
Current or planned administration of another parenteral GP IIb/IIIa inhibitor.
Dependency on renal dialysis.
Known hypersensitivity to any component of the product.

@@ Line 16: / Line 16: @@
 * Dependency on [[renal dialysis]].
 * Known [[hypersensitivity]] to any component of the product.
+<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = INTEGRILIN (EPTIFIBATIDE) INJECTION, SOLUTION [MERCK SHARP & DOHME CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ad82e30-50d8-450c-8a2a-b4b507ed1ce2 | publisher =  | date =  | accessdate = 5 February 2014 }}</ref>